Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vapendavir (Primary)
Indications Rhinovirus infections
Focus Therapeutic Use
Acronyms SPIRITUS
Sponsors Aviragen Therapeutics

Most Recent Events

24 May 2017 Baseline characteristics presented at the 113th International Conference of the American Thoracic Society
13 Feb 2017 Top-line results published in an Aviragen Therapeutics media release.
13 Feb 2017 According to an Aviragen Therapeutics media release, this trial was conducted at approximately 68 sites in North America and Europe.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com